Abstract
The incorporation of tyrosine kinase inhibitors (TKIs) into chemotherapy regimens has significantly improved the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Second and third generation TKIs with increased potency against BCR-ABL1 and enhanced activity against ABL1 kinase domain mutations have been evaluated in a number of studies showing significant promise. In particular, ponatinib, a potent pan-BCR-ABL1 TKI capable of overcoming the T315I mutation, is of significant interest in the treatment of Ph+ ALL, as a number of reports have shown a high incidence of T315I mutants at relapse.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
